DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Deutsche Boerse AG 11:34:32 05/07/2024 pm IST | ||
| 0.001 EUR | 0.00% |
|
| 3 months | -99.33% | ||
| 6 months | -99.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 0.001 | 0.00% |
| 04/24/04 | 0.001 | -92.31% |
| 03/24/03 | 0.013 | +1,200.00% |
| 02/24/02 | 0.001 | 0.00% |
| 01/24/01 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 11:34 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM37QD |
| ISIN | DE000VM37QD8 |
| Date issued | 19/10/2023 |
| Strike | 100 $ |
| Maturity | 20/09/2024 (77 Days) |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.86 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
